RepliCel Life Sciences Inc.

As of September 30, 2023, RepliCel Life Sciences Inc. carries a market capitalization of 5.49M, placing it among publicly traded companies globally. Its enterprise value stands at 5.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2023, RepliCel Life Sciences Inc. has 65.00M shares outstanding.

These figures are as of September 30, 2023. The price-to-sales ratio is 18.04, and the price-to-book ratio stands at -1.12.

These figures are as of September 30, 2023. The EV/Sales ratio of 21.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.50M versus a market cap of 5.49M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2023, RepliCel Life Sciences Inc. maintains a current ratio of 0.13, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -0.62, indicating conservative leverage, while an interest coverage ratio of -811.62 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) is negative at -17.58, reflecting losses generated across the asset base. The company generates approximately 130,269.94 in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 19, 2026, RepliCel Life Sciences Inc.'s stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.07.

Over the twelve months ended September 30, 2023, RepliCel Life Sciences Inc. generated 260,539.88 in revenue and converted that into -51,032.63 in net income, yielding earnings per share of 0.00. EBITDA reached -1.08M, while operating income came in at -1.01M.

As of September 30, 2023, RepliCel Life Sciences Inc. holds 23,921.34 in cash and equivalents against 30,165.72 in total debt, resulting in a net debt position of 18,949.69. Total book value stands at -4.89M, with working capital of -971,395.01 providing operational flexibility.

RepliCel Life Sciences Inc. produced -1.47M in operating cash flow over the twelve months ended September 30, 2023.

These figures cover the twelve months ended September 30, 2023. The operating margin of -387.01 and net profit margin of -19.59 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -31.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.88, meaning RepliCel Life Sciences Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

RepliCel Life Sciences Inc.'s most recent stock split took place on August 10, 2016 with a 10:1 split ratio.

As of September 30, 2023, RepliCel Life Sciences Inc. has an Altman Z-Score of -208.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.